<p>Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percentages of CD4<sup><b>+</b></sup>T (B) and CD8<sup><b>+</b></sup>T (C) cells in lymphocytes of healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. The numbers examined at each time point were: HC = 18, and MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23, 6M = 20, 12M = 18. The horizontal bars indicate the mean values. W = week; M = month. ***<i>p</i><0.0001, *<i>p</i><0.05.</p
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
Background Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte e...
<p>(A) The levels of Sema4A are not affected by fingolimod. The serum Sema4A levels were measured be...
<p>Effects of fingolimod on phenotypically distinct CD4<sup>+</sup>T (A) and CD8<sup>+</sup>T (B) ce...
BACKGROUND:Treatment with fingolimod reduces inflammation in multiple sclerosis (MS) by inhibiting l...
<p>PBMCs of MS patients before (t0, n = 16) or after three months of treatment by fingolimod (t3, n ...
<p>Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4<sup>+...
Background Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclero...
Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple ...
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of ...
Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from ...
Introduction: Multiple sclerosis (MS) is associated with the failure of peripheral tolerance to self...
BackgroundFingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long...
Abstract Multiple sclerosis (MS) is a complex neurological disease where, in genetically predisposed...
<p>The median and range are shown. Lymphoid cells were gated according to their FSC/SSC profile.</p>...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
Background Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte e...
<p>(A) The levels of Sema4A are not affected by fingolimod. The serum Sema4A levels were measured be...
<p>Effects of fingolimod on phenotypically distinct CD4<sup>+</sup>T (A) and CD8<sup>+</sup>T (B) ce...
BACKGROUND:Treatment with fingolimod reduces inflammation in multiple sclerosis (MS) by inhibiting l...
<p>PBMCs of MS patients before (t0, n = 16) or after three months of treatment by fingolimod (t3, n ...
<p>Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4<sup>+...
Background Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclero...
Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple ...
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of ...
Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from ...
Introduction: Multiple sclerosis (MS) is associated with the failure of peripheral tolerance to self...
BackgroundFingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long...
Abstract Multiple sclerosis (MS) is a complex neurological disease where, in genetically predisposed...
<p>The median and range are shown. Lymphoid cells were gated according to their FSC/SSC profile.</p>...
Objective:Fingolimod is approved for the treatment of highly active relapsing remitting multiple scl...
Background Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte e...
<p>(A) The levels of Sema4A are not affected by fingolimod. The serum Sema4A levels were measured be...